MSC Stem Cell Injections for Cervical Radiculopathy with Cord Compression
There is currently no high-quality evidence supporting mesenchymal stem cell (MSC) injections for cervical radiculopathy with cord compression, and established surgical decompression remains the evidence-based standard of care.
Current Evidence-Based Treatment
The provided guidelines focus exclusively on surgical decompression for cervical radiculopathy, with anterior cervical decompression (with or without fusion) demonstrating Class I evidence for rapid relief of arm/neck pain, weakness, and sensory loss within 3-4 months 1. Nonoperative management succeeds in approximately 90% of acute cases, but when nerve root compression is visible on imaging and conservative measures fail, surgical decompression is recommended 1.
MSC Research Status
Spinal Cord Injury Studies (Not Radiculopathy)
The available research addresses spinal cord injury (SCI), not cervical radiculopathy with cord compression—these are distinct clinical entities:
Most recent placebo-controlled trial (2026): Intrathecal Wharton's jelly-derived MSCs in chronic incomplete cervical SCI showed no significant between-group differences compared to placebo, despite being safe and well-tolerated 2. Both groups improved equally, suggesting natural recovery or placebo effects.
Phase III trial (2016): Single-dose autologous bone marrow MSCs in chronic cervical SCI showed very weak therapeutic effect—only 2 of 16 patients demonstrated neurological improvement 3. The authors concluded multiple injections might be necessary.
Earlier uncontrolled studies (2012-2013): Small case series reported some motor improvements in 3 of 10 patients 4 and 10 of 20 patients 5, but these lacked control groups and cannot establish efficacy.
Critical Limitations
None of these studies address your specific clinical scenario of cervical radiculopathy with cord compression. The pathophysiology differs fundamentally:
- Radiculopathy: Mechanical nerve root compression requiring decompression
- SCI: Traumatic cord injury with inflammation, demyelination, and axonal loss where MSCs theoretically modulate inflammation and promote repair
Safety Considerations
While MSC therapy appears generally safe in SCI trials 2, 4, 5, 3, intravascular MSC delivery carries documented risks including thrombosis and embolization, particularly with products from adipose and perinatal tissues that may express high levels of tissue factor 6. This is especially concerning given that cervical cord compression already compromises vascular supply.
Clinical Recommendation Algorithm
For cervical radiculopathy with cord compression:
First-line: Conservative management (physical therapy, cervical collar immobilization) for acute presentations—90% success rate 1
If conservative treatment fails after 3-4 months AND imaging confirms nerve root/cord compression: Proceed to anterior cervical decompression ± fusion (Class I evidence) 1
MSC therapy: Currently not recommended due to:
- Zero evidence in this specific condition
- Established surgical alternatives with proven efficacy
- Potential thrombotic risks with cord compression
- Even in SCI (where mechanism is more plausible), the most rigorous trial showed no benefit 2
Future Considerations
Network meta-analysis suggests umbilical cord MSCs via intrathecal injection may be optimal for SCI 7, and functionalized MSCs with biomaterial delivery platforms show preclinical promise 8, 9. However, these remain experimental approaches requiring standardized protocols, potency criteria, and adequately powered randomized trials before clinical application 9, 10.
Bottom line: Pursue evidence-based surgical decompression for symptomatic cervical radiculopathy with cord compression. MSC therapy lacks any supporting evidence for this indication and should only be considered within properly designed clinical trials.